THE CLINICAL EXPERIMENT OF CEFUROXIME AXETIL (CXM-AX) IN EXTERNAL EYE DISEASES AND THE PENETRATION INTO THE TEAR OF HUMAN EYES

DOI
  • YATA KOJI
    Department of Ophthalmology, Kyorin University, School of Medicine
  • SHIMIZU CHIHIRO
    Department of Ophthalmology, Kyorin University, School of Medicine
  • TOKUDA HISAYA
    Department of Ophthalmology, Kyorin University, School of Medicine

Bibliographic Information

Other Title
  • 眼科学領域におけるCefuroxime axetil (CXM-AX) の臨床的・基礎的検討

Abstract

Cefuroxime axetil (CXM-AX, SN 407), a new oral cephalosporin antibiotic, was administered to a total of 28 patients, i. e. 7 patients with hordeolum and 21 patients with meibomitis, to evaluate its clinical efficacy. 250 mg or 500 mg CXM-AX was given after meal three times a day, and the duration of administration ranged 2-12 days. The clinical efficacy was excellent in 16 patients, good in 11 and fair in 1, the efficacy rate being 96.4%. As for adverse events, gastric discomfort was observed in one patient, and diarrhea in another. They were, however, mild and rapidly disappeared on the next day of withdrawal of CXM-AX.<BR>After a single dose of 250 mg CXM-AX given after meal to healthy volunteers, CXM levels in tear and serum were determined. The peaks of CXM levels in tear were achieved at about 2 hrs after dosing, and the mean peak level was 0.33 μg/ml, which corresponded to about 10% of mean serum level of 3.10 μg/ml obtained at the time.<BR>The ratio of concentrations in tear to those in serum was similar to that of cephalexin, another cephalosporin.

Journal

  • CHEMOTHERAPY

    CHEMOTHERAPY 34 (Supplement5), 1104-1107, 1986

    Japanese Society of Chemotherapy

Details 詳細情報について

Report a problem

Back to top